Aayushi Pratap

New York, United States

Associate Editor at C&EN

Business Reporter @ C&EN Formerly@Forbes@GenomeWeb@Hindustan Times ||@ColumbiaJourn @PharmaCorrespondent @eurekalert fellow||

Featured in: Favicon

genomeweb.com Favicon

forbes.com Favicon

hindustantimes.com Favicon

sciencenews.org Favicon

forbes.com.br Favicon

forbesjapan.com Favicon

forbes.es

forbesmiddleeast.com Favicon

realclearscience.com Favicon

endpts.com + 9 more

Articles

AI start-up raises $11 million to make drug formulations better

3 weeks ago | cen.acs.org | Aayushi Pratap

In the world of drug discovery and clinical trials, drug formulation can make or break a product's success, yet its role often goes underappreciated, says Christine Allen, cofounder and CEO of Intrepid Labs, a Toronto-based start-up that has emerged from stealth. Her company has secured $11 million in preseed and seed funding to rethink drug formulation with the use of robotics and artificial intelligence (AI).
Drug services firms begin embracing AI

3 weeks ago | cen.acs.org | Aayushi Pratap

It's hard nowadays for any big company to distance itself from artificial intelligence and its subset, machine learning. Drug services firms are no exception. These technologies are slowly picking up momentum among contract development and manufacturing organizations (CDMOs) to innovate drug synthesis and automate quality control processes that humans have traditionally managed. It's hard nowadays for any big company to distance itself from artificial intelligence and its subset, machine learning.
Trump executive order aims to reshore US drug production

1 month ago | cen.acs.org | Aayushi Pratap

President Donald J. Trump has signed an executive order that seeks to do what past presidents, including Trump himself in his previous administration, did not succeed in doing: increasing US production of drugs and pharmaceutical ingredients. The order, signed May 5, intends to lower regulatory barriers for companies looking to expand or set up new drug manufacturing facilities in the US.
Lilly touts results for once-daily weight-loss and antidiabetic pill

1 month ago | cen.acs.org | Aayushi Pratap

The race to develop small-molecule alternatives to peptide-based weight-loss and antidiabetes drugs isn't over, but a leader and a laggard have emerged. Eli Lilly and Company, which already markets weight-loss and diabetes drugs that must be injected, is a step closer to introducing a once-daily pill for the same conditions.
Colorado start-up launches to improve drug discovery chemistry

2 months ago | cen.acs.org | Aayushi Pratap

A new company has entered the drug discovery space with what it calls a "chemistry-first" platform. Colorado-based Cime Therapeutics has emerged from stealth with $2.1 million in preseed financing to advance its method for efficiently synthesizing and screening molecules that could become oncology drugs.
Disheartened by funding cuts, international students look beyond the US

2 months ago | cen.acs.org | Aayushi Pratap

Credit: Madeline Monroe/C&ENFor chemistry students across the globe, coming to the US to pursue graduate education is often the dream. Ample funding, access to cutting-edge research facilities, and the ease of transitioning into industry from academia have attracted international talent to the US for decades. But for many, that dream has suddenly been upended. Research funding cuts by the second Donald J.
Disheartened by funding cuts, international students look beyond the US

2 months ago | cen.acs.org | Aayushi Pratap

For chemistry students across the globe, coming to the US to pursue graduate education is often the dream. Ample funding, access to cutting-edge research facilities, and the ease of transitioning into industry from academia have attracted international talent to the US for decades. But for many, that dream has suddenly been upended. Research funding cuts by the second Donald J.
Boston AI start-up raises $200 million

2 months ago | cen.acs.org | Aayushi Pratap

After 2 years in stealth, a Cambridge, Massachusetts-based start-up has emerged with plans to conduct science in automated laboratories that run on a special version of artificial intelligence. Lila Sciences has secured $200 million in seed funding from Flagship Pioneering, which incubated the company, and General Catalyst, March Capital, Ark Venture Fund, and others.
Can tiny lab-grown plants solve a big vaccine problem?

Feb 12, 2025 | cen.acs.org | Aayushi Pratap

Chile is home to the rare soapbark tree, known in the scientific community as Quillaja saponaria. These evergreens, which can stand 15 to 20 m tall and take a quarter of a century to mature, are by no means ordinary. All their organs-but especially the bark-contain soapy compounds called saponins that have been used in skin-care creams, beverages, detergents, and cough and cold remedies for over a century.
AI drug discovery start-up Manas secures $24.6 million in funding

Feb 7, 2025 | cen.acs.org | Aayushi Pratap

By Manas AI, an artificial intelligence drug discovery venture cofounded by the LinkedIn founder Reid Hoffman and the cancer researcher Siddhartha Mukherjee, has raised $24.6 million in seed funding. The start-up says it will use its AI platform to screen vast chemical libraries and find drug candidates for treating cancers, autoimmune diseases, and rare conditions. Manas says it has partnered with Microsoft to access that firm's Azure cloud computing platform.